Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:2022
gptkb:FDA |
| gptkbp:average_temperature |
-20 degrees Celsius
|
| gptkbp:brand |
Imvamune
Imvanex |
| gptkbp:clinical_trial |
Phase 3 trials
|
| gptkbp:clinical_use |
post-exposure prophylaxis
pre-exposure prophylaxis |
| gptkbp:contraindication |
severe allergic reactions
not for immunocompromised individuals |
| gptkbp:developed_by |
Bavarian Nordic
|
| gptkbp:dosage_form |
two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
JYNNEOS
|
| gptkbp:is_vulnerable_to |
varies by region
ongoing studies July 2022 limited supply single-dose vial monitored by health authorities available through public health programs adverse event reporting required live attenuated virus CDC guidelines requires reconstitution 85% effective against monkeypox aims to control outbreaks freeze-dried increased during outbreaks not evaluated for smallpox |
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
headache muscle pain nausea fever chills injection site reactions lymphadenopathy |
| gptkbp:target_audience |
high-risk individuals
|
| gptkbp:used_for |
prevention of monkeypox
prevention of smallpox |
| gptkbp:vaccine_indications |
recommended for at-risk populations
|
| gptkbp:vaccine_research_focus |
immunogenicity studies
|
| gptkbp:vaccine_stability |
stable for 24 months at -20 degrees Celsius
stable for 6 months at 2-8 degrees Celsius |